References

1. Barnes RA, Stallard N: Severe infections after bone marrow transplantation. Curr Opin Crit Care 7:362-366, 2001.

2. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR 49(RR-10):1-125, 2000.

3. Kusne S, Krystofiak S: Infection control issues after bone marrow transplantation. Curr Opin Infect Dis 14:427-431, 2001.

4. Sable CA, Donowitz GR: Infections in bone marrow transplant recipients. Clin Infect Dis 18:273-284, 1993.

5. van Burik JA, Weisdorf: Hematopoietic stem cell therapy: infections in recipients of blood and marrow transplantation. Hemat/Oncol Clin North Am 13:1065-1089, 1993.

6. Shenep JL: Viridans-group streptococcal infections in immunocompromised hosts. Internat J Antimicrob Agents 14:129-135, 2000.

7. Elishoov H, Or R, Strauss N, et al.: Nosocomial colonization, septicemia, and Hickman-Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study. Medicine (Baltimore) 77:83-101, 1998.

8. Mossad SB, Longworth DL, Goormastic M, et al.: Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 18:265-271, 1996.

9. Steiner M, Villablanca J, Kersey J, et al.: Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol 42:354-358, 1993.

10. Alcaide F, Linares JA, Pallares R, et al.: In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group Streptococci isolated from blood. Antimicrob Agents Chemother 39: 2243-2247, 1995.

11. Kirkpatrick BD, Harrington SM, Smith D, et al.: Outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. Clin Infect Dis 29: 1268-1273, 1999.

12. Cox GJ, Matsui SM, Lo RS, et al.: Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 107:1398-1407, 1994.

13. Kadakia MP, Rybka WB, Stewart JA, et al.: Human herpes virus 6: infection and disease following autologous and allogeneic bone marrow transplantation. Blood 87: 5341-5354, 1996.

14. Imbert-Marcille BM, Tang XW, Lepelletier D, et al.: Human herpes virus 6 infection after autologous or allo-geneic stem cell transplantation: a single-center prospective longitudinal study of 92 patients. Clin Infect Dis 31: 881-886, 2000.

15. Zerr DM, Gooley TA, Yeung L, et al.: Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis 33:763-771, 2001.

16. Luppi M, Barozzi P, Schultz TF, et al.: Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood 96:2355-2357, 2000.

17. Yoshikawa T: Human herpesvirus-6 and 7 infections in transplantation. Pediatr Transplant 7:11-17, 2003.

18. Harrington RD, Hooten TM, Hackman RC, et al.: An outbreak of respiratory syncytial virus infection in a bone marrow transplant center. J Infect Dis 165:987-993, 1992.

19. Weinstock DM, Eagen J, Malak SA, et al.: Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol 21:730-732, 2000.

20. Ljunman P, Ward KN, Crooks BNA, et al.: Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transplant 28:479-484, 2001.

21. Nichols WG, Guthrie KA, Corey L, et al.: Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39:1300-1306, 2004.

22. Nichols WG, Corey L, Gooley T, et al.: Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98:573-578, 2001.

23. Hale GA, Heslop HE, Krance RA, et al.: Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 23:277-282, 1999.

24. Goodman JL, Winston DJ, Greenfield RA, et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845-851, 1992.

25. Slavin MA, Osborne B, Adams R, et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 171:1545-1552, 1995.

26. De La Rosa GR, Champlin RE, Kontoyiannis DP: Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transplant Infect Dis 4:3-9, 2002.

27. Wald A, Leisenring, van Burik J, Bowden R: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459-1466, 1997.

28. Nucci M, Marr KA, Queiroz-Telles F, et al.: Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 38:1237-1242, 2004.

29. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al.: Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 39:584-587, 2004.

30. Imhof A, Balajee A, Fredricks DN, et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39:743-746, 2004.

31. Fridkin SK: Vancomycin-intermediate and resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 32:108-115, 2001.

32. Jaffe D, Jakubowski A, Sepkowitz K, et al.: Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis 39:1625-1632, 2004.

33. Cruciani M, Rampazzo R, Malena M, et al.: Prophylaxis with fluoroquinolones for bacterial infections in neu-tropenic patients: a meta-analysis. Clin Infect Dis 23:795-805, 1996.

34. Spielberger R, Stiff P, Bensinger W, et al.: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590-2598, 2004.

35. Epstein JB, Ransier A, Sherlock CH, et al.: Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Eur J Cancer Biol Oral Oncol 32B:158, 1996.

36. van-Burik JH, Ratanatharathorn V, Stepan DE, et al.: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407-1416, 2004.

37. Walsh TJ, Teppler H, Donowitz G, et al.: Caspofungin versus liposomal amphotericin B for empirical antifun-gal therapy in patients with persistent fever and neu-tropenia. N Engl J Med 351:1391-1402, 2004.

38. Lin S, Schranz J, Teutsch S: Aspergillosis case fatality rate: systematic review of the literature. Clin Infect Dis 32:358-366, 2001.

39. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415, 2002.

40. Maertens J, Raad I, Petrikkos G, et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional anti-fungal therapy. Clin Infect Dis 39:1563-1571, 2004.

41. Marr K, Boeckh M, Carter RA, et al.: Combination anti-fungal therapy for invasive aspergillosis. Clin Infect Dis 39:797-802, 2004.

42. Flomenberg P, Babbitt J, Dobryski W: Increasing incidence of adenovirus in bone marrow transplant recipients. J Infect Dis 169:775-781, 1994.

43. Harrington RD, Woolfrey AE, Bowden R, et al.: Legionellosis in a bone marrow transplant center. Bone Marrow Transplant 18:361-368, 1996.

44. Kool JL, Fiore AE, Kioski CM, et al.: More than 10 years of unrecognized nosocomial transmission of Legionnaires' disease among transplant patients. Infect Control Hosp Epidemiol 19:898-904, 1998.

45. Chang J, Powles R, Paton N, et al.: Listeriosis in bone marrow transplant recipients: incidence, clinical features, and treatment. Clin Infect Dis 21:1289-1290, 1995.

46. Tuan IZ, Dennison D, Weisdorf D: Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 10:267-272, 1992.

47. Mele A, Paterson PJ, Prentice HG, et al.: Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant;29:691-698, 2002.

48. Liu LX, Weller PF: Strongyloidiasis and other intestinal nematode infections. Infect Dis Clin North Am 6:655-682, 1993.

49. Nichols WG, Corey L, Gooley T, et al.: High risk of death due to bacterial and fungal infections among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence of indirect effects of primary CMV infection. J Infect Dis 185:273-282, 2002.

50. Reed EC, Bowden RA, Davidliker PS, et al.: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109: 783-788, 1988.

51. Wolf D, Lurain N, Zuckerman T, et al.: Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 101: 463-465, 2003.

52. Slavin MA, Meyers JD, Remington JS, et al.: Toxoplasma gondii infection in marrow transplant recipients: a 20-year experience. Bone Marrow Transplant 13:549-557, 1994.

53. Winston DJ, Yeager AM, Chandrasekar PH, et al.: Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 36:749-758, 2003.

54. Boeckh M, Gooley TA, Myerson D, et al.: Cytomegalovirus pp65 antigenemia- guided early treatment with ganci-clovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double blind study. Blood 88:4063-4071, 1996.

55. Boeckh M, Leisenring W, Riddell S, et al.: Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407-414, 2003.

56. Chang CS, Miller W, Haake R, et al.: Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 13:277-283, 1994.

57. Zutter MM, Martin PJ, Sale GE, et al.: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520-529, 1988.

58. Gerritsen EJ, Stam ED, Hermans J, et al.: Risk factors for developing EBV-related B cell lymphoproliferative disorders (BPLD) after non-HLA-identical BMT in children. Bone Marrow Transplant 18:377-382, 1996.

59. Doucette K, Fishman J: Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 38:1428-1439, 2004.

60. Cordonnier C, Martino R, Trabasso P, et al.: Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis 38: 1229-1236, 2004.

61. Rooney CM, Smith CA, Ng CY, et al.: Infusion of cytoxic T cells for the prevention of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555, 1998.

This page intentionally left blank

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment